Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

1 results
12:00 AM, Sep 15, 2014  |  BC Week In Review | Company News  |  Sales & Marketing

Chugai sales and marketing update

Chugai launched Alecensa alectinib in Japan to treat unresectable, recurrent or advanced anaplastic lymphoma kinase (ALK)-positive …
Basel, Switzerland), which is the majority owner of Chugai, has rights to the compound elsewhere. Alecensa